The Korean Journal of Nuclear Medicine (대한핵의학회지)

The Korean Society of Nuclear Medicine (대한핵의학회)
권호 표지

MR Contrast Agents and Molecular Imaging

MR조영제와 분자영상

  • Moon, Woo-Kyung (Department of Radiology, College of Medicine, Seoul National University)
  • 문우경 (서울대학교 의과대학 방사선과학교실)
  • Published : 2004.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

The two major classes of magnetic resonance (MR) contrast agents are paramagnetic contrast agents, usually based on chelates of gadolinium generating T1 positive signal enhancement, and super-paramagnetic contrast agents that use mono- or polycrystalline iron oxide to generate strong T2 negative contrast in MR images. These paramagnetic or super-paramagnetic complexes are used to develop new contrast agents that can target the specific molecular marker of the cells or tan be activated to report on the physiological status or metabolic activity of biological systems. In molecular imaging science, MR imaging has emerged as a leading technique because it provides high-resolution three-dimension maps of the living subject. The future of molecular MR imaging is promising as advancements in hardware, contrast agents, and image acquisition methods coalesce to bring high resolution in vivo imaging to the biochemical sciences and to patient care.

Keywords

References

  1. Lee JW, Moon WK, Weinmann HJ, Kim SJ, Kim JH, Park SH, et al. Contrast-enhanced MR imaging of postoperative scars and VX2 carcinoma in rabbits: comparison of macromolecular contrast agent and gadopentetate dimeglumine. Radiology 2003;229:132-9. https://doi.org/10.1148/radiol.2291020218
  2. Moon WK, Chang KH, Weinmann HJ, Koh YH, Im JG, Yeon KM, et al. Dynamic contrast-enhanced MR imaging of abscess and carcinoma in rabbits: comparison of gadopentetate dimeglumine and a macromolecular contrast agent. Am J Roentgenol 2000;174:1385-90. https://doi.org/10.2214/ajr.174.5.1741385
  3. Kim YH, Choi BI, Cho WH, Lim S, Moon WK, Han JK, et al. Dynamic contrast-enhanced MR imaging of VX2 carcinomas after X-irradiation in rabbits: comparison of gadopentetate dimeglumine and a macromolecular contrast agent. Invest Radiol 2003;38:539-49. https://doi.org/10.1097/01.RLI.0000073720.97820.ab
  4. Lewin M, Carlesso N, Tung CH. Tat peptide-derivatized magnetic nanoparticle allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol 2000;18:410-4. https://doi.org/10.1038/74464
  5. Matsumura A, Shibata Y, Nakagawa K, Nose T. MRI contrast enhancement by Gd-DTPA-monoclonal antibody in 9L glioma rats. Acta Neurochir Suppl 1994;60:356-8.
  6. Artemov D, Mori N, Ravi R, Bhujwalla ZM. Magnetic resonance molecular imaging of the Her-2/neu receptor. Cancer Res 2003;63:2723-7.
  7. Schellenberger EA, Bogdanov A Jr, Hogemann D, Tait J, Weissleder R, Josephson L. Annexin V-CLIO: a nanoparticle for detecting apoptosis by MRI. Mol Imaging 2002;1:102-7. https://doi.org/10.1162/153535002320162769
  8. Weissleder R, Moore A, Mahmood U, Bhorade R, Benveniste H, Chiocca EA, et al. In vivo magnetic resonance imaging of transgene expression. Nat Med 2000;6:351-5. https://doi.org/10.1038/73219
  9. Kircher MF, Mahmood U, King RS, Weissleder R, Josephson L. A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res 2003;63:8122-5.
  10. Moon WK, Lin Y, O'Loughlin T, Tang Y, Kim DE, Weissleder R, et al. Enhanced tumor detection using a folate receptor-targeted near-infrared fluorochrome conjugate. Bioconjug Chem 2003;14:539-45. https://doi.org/10.1021/bc0340114
  11. Meade TJ, Taylor AK, Bull SR. New magnetic resonance contrast agents as biochemical reporters. Curr Opin Neurobiol 2003;13:597-602. https://doi.org/10.1016/j.conb.2003.09.009
  12. Perez JM, Josephson L, O'Loughlin T, Hogemann D, Weissleder R. Magnetic relaxation switches capable of sensing molecular interactions. Nat Biotechnol 2002;20:816-20. https://doi.org/10.1038/nbt720
  13. Lee SC, Kim K, Kim J, Lee S, Yi JH, Kim WS, et al. One micrometer resolution NMR microscopy. J Magn Reson 2001;150:207-13. https://doi.org/10.1006/jmre.2001.2319
  14. Jennings D, Hatton BN, Guo J, Galons JP, Trouard TP, Raghunand N, et al. Early response of prostate carcinoma xenografts to docetaxel chemotherapy monitored with diffusion MRI. Neoplasia 2002;4:255-62. https://doi.org/10.1038/sj.neo.7900225
  15. Stegman L, Rehemtulla A, Beattie B. Noninvasive quantitation of cytosine deaminase transgene expression in human tumor xenografts with in vivo magnetic resonance spectroscopy. Proc Natl Acad Sci USA 1999;96:9821-6. https://doi.org/10.1073/pnas.96.17.9821